(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
0.00% $ 0.00110
Live Chart Being Loaded With Signals
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers...
Stats | |
---|---|
Dagens volum | 943.00 |
Gjennomsnittsvolum | 1 281.00 |
Markedsverdi | 46 293.00 |
EPS | $-0.0658 ( 2023-08-11 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-11-23 | Greenspan Ira Scott | Sell | 3 000 000 | W Warrants |
2021-11-23 | Lamstein Joshua R | Sell | 3 000 000 | W Warrants |
2021-06-01 | Hopper Paul | Buy | 6 333 | Common Stock |
2020-12-15 | Hopper Paul | Buy | 0 | Common Stock |
2020-12-15 | Hopper Paul | Sell | 0 | Common Stock |
INSIDER POWER |
---|
0.00 |
Last 55 transactions |
Buy: 2 180 518 | Sell: 6 965 870 |
Scopus Biopharma Inc. Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
KTTA | 0.932 |
ISPO | 0.915 |
UTME | 0.91 |
SMIT | 0.91 |
MTP | 0.909 |
CREG | 0.908 |
NCBS | 0.906 |
HOL | 0.905 |
NKTX | 0.904 |
SWVL | 0.902 |
10 Mest negative korrelasjoner | |
---|---|
GDNR | -0.933 |
AMYT | -0.924 |
NWLI | -0.913 |
BRAC | -0.911 |
EMLD | -0.91 |
BTWN | -0.91 |
CDZI | -0.909 |
AVAC | -0.909 |
PROF | -0.908 |
EXAS | -0.908 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Scopus Biopharma Inc. Økonomi
Annual | 2022 |
Omsetning: | $0 |
Bruttogevinst: | $0 (0.00 %) |
EPS: | $-0.550 |
FY | 2022 |
Omsetning: | $0 |
Bruttogevinst: | $0 (0.00 %) |
EPS: | $-0.550 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-2.02 |
FY | 2020 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-0.810 |
Financial Reports:
No articles found.
Scopus Biopharma Inc.
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.